Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 735-744

  Luiten, R M ^a   Coney, L R ^b   Fleuren, G J ^a   Warnaar, S O ^a   Litvinov, S V ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Apollon   (United States)

Author keywords

Chimeric bispecific monoclonal antibody; G250 antigen; Immunotherapy; Renal cell carcinoma

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL CLONE; CONTROLLED STUDY; CYTOLYSIS; DNA TRANSFECTION; DRUG BINDING; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; MYELOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TARGET CELL;

EID: 0029760316     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.430     Document Type: Article

References (45)

1. ABRAMS JS, RAYNER AA, WIERNIK PH, PARKINSON DR, EISENBERGER M, ARONSON FR, GUCALP R, ATKINS MB AND HAWKINS MJ. (1990). High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J. Natl Cancer Inst., 82, 1202 1206.
2. BERG J, LOTSCHER E, STEIMER KS, CAPON DJ, BAENZIGER J, JACK HM AND WABL M. (1991). Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc. Natl Acad. USA, 88, 4723-4727.
3. BOLHUIS RL, LAMERS CH, GOEY SH, EGGERMONT AM, TRIMBOS JB, STOTER G, LANZAVECCHIA A, DI RE E, MIOTTI S, RASPAGLIESI F, RIVOLTINI L AND COLNAGHI MI. (1992). Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer (suppl.), 7, 78 81.
4. BRISSINCK J, DEMANET C, MOSER M, LEO O AND THIELEMANS K. (1991). Treatment of mice bearing bcl1 lymphoma with bispecific antibodies. J. Immulol., 147, 4019-4026.
5. BUKOWSKI RM, SHARFMAN W, MURTHY S, RAYMAN P, TUBBS R, ALEXANDER J, BUDD GT, SERGI JS, BAUER L, GIBSON V, STANLEY J, BOYETT J, PONTES E AND FINKE JH. (1991). Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res., 51, 4199-4205.
6. CANEVARI S, STOTER G, ARIENTI F, BOLIS G, COLNAGHI MI, DIRE EM, EGGERMONT AM, GOEY SH, GRATAMA JW, LAMERS CH, NOOY MA, PARMIANI G, RASPAGLIESI F, RAVAGNANI F, SCARFONE G, TRIMBOS JB, WARNAAR SO AND BOLHUIS RLH. (1995). Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl Cancer Inst., 87, 1463 1469.
7. CONEY LR, SANBORN D, LAMERS CHL, ZURAWSKI VC Jr AND WARNAAR SO. (1996). A chimeric bispecific antibody that exhibits potent cytolysis of tumor cell lines expressing the tumor-associated folate receptor and decreased immunogenicity in patients (submitted for publication).
8. COURTNAY-LUCK NS, EPENETOS AA, MOORE R, LARCHE M, PECTASIDES D, DHOKIA B AND RITTER MA. (1986). Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res., 46, 6489-6493.
9. DE LAU WBM, HEIJE K, NEEFJES JJ, OOSTERWEGEL M, ROZEMULLER E AND BAST BJEG. (1991). Absence of preferential homologous H/L chain association in hybrid hybridomas. J. Immuno., 146, 906-914.
10. DIJK VAN J, OOSTERWIJK E, KROONENBURGH VJPG, JONAS U, FLEUREN GJ, PAUWELS EKJ AND WARNAAR SO. (1988). Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J. Nucl. Med., 29, 1078-1082.
11. DIJK VAN J, WARNAAR SO, EENDENBURG VDH, THIENPONT M, BRAAKMAN E, BOOT JHA, FLEUREN GJ AND BOLHUIS RLH. (1989). Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int. J. Cancer, 43, 344-349.
12. DIJK VAN J, ZEGVELD ST, FLEUREN GJ AND WARNAAR SO. (1991). Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of and size affinity. Int. J. Cancer, 48, 738-743.
13. DIJK VAN J, UEMURA H, BENIERS AJMC, PEELEN WP, ZEGVELD ST, FLEUREN GJ, WARNAAR SO AND OOSTERWIJK E. (1994). Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int. J. Cancer, 56, 262-268.
14. ERNSTOFF MS, GOODING W, NAIR S, BAHNSON RR, MIKETIC LM, BANNER B, DAY R, WHITESIDE T, TITUS-ERNSTOFF L AND KIRKWOOD JM. (1992). Immunological effects of treatment with sequential administration of recombinant interferon gamma and 3 in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res., 52, 851-856.
15. FANGER MW, SEGAL DM AND WUNDERLICH JR. (1990). Going both ways: bispecific antibodies and targeted cellular cytotoxicity. Science, 4, 2846 2849.
16. FERUGLIO C, ZAMBELLO R, TRENTIN L, BULIAN P, FRANCESCHI T, CETTO GL AND SEMENZATO G. (1992). Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy: effects of activation with recombinant interleukin-2. Cancer, 69, 2525-2531.
17. FISHER RI, COLTMAN CA, DOROSHOW JH, RAYNER AA, HAWKINS MJ, MIER JW, WIERNIK P, MCMANNIS JD, WEISS GR, MARGOLIN KA, GEMLO BT, HOTH DF, PARKINSON DR AND PAIETTA E. (1988). Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med., 108, 518-523.
18. FOON KA, WALTHER PJ, BERNSTEIN ZP, VAICKUS L, RAHMAN R, WATANABE H, SWEENEY J, PARK J, VESPER D, RUSSELL D, WALKER RA, DARROW TL, JUHANI LINNA T, FARMER DL, LYNCH WJ JR, HUBEN R AND GOLDROSEN MH. (1992). Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J. Immunother., 11, 184 190.
19. GARRIDO MA, VALDAYO MJ, WINKLER DF, TITUS JA, HECHT TT, PEREZ P, SEGAL DM AND WUNDERLICH JR. (1990). Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res., 50, 4227 4232.
20. GAYNOR ER, WEISS GR, MARGOLIN KA, ARONSON FR, SZNOL M, DEMCHAK P, GRIMA KM, FISHER RI, BOLDT DH, DOROSHOW JH, BAR MH, HAWKINS MJ, MIER JW AND CALIENDO G. (1990). Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J. Natl Cancer Inst., 82, 1397 1402.
21. HAYAT K, RODGERS S, BRUCE L, REES RC, CHAPMAN K, REEDER S, DORREEN MS, SHERIDAN E, SREENIVASAN T AND HANCOCK BW. (1991). Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2. Eur. J. Cancer, 27, 1009 1014.
22. JENSEN PB AND BIRCH C. (1990). Low-dose regimen of inlerleukin-2 for metastatic renal carcinoma. Lancet, 335, 1522 1523.
23. KRIGEL RL, PADAVIC-SHALLER KA, RUDOLPH AR, KONRAD M, BRADLEY EC AND COMIS RL. (1990). Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon. J. Clin. Oncol., 8, 460 467.
24. KROESEN BJ, TER HAAR A, SPAKMAN H, WILLEMSE P, SLEIJFER DT, DE VRIES EGE, MULDER NH, BERENDSEN HH, LIMBURG PC, THE TH AND DE LEIJ L. (1993). Local antitumour treatment in carcinoma patients with bispecitic-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother., 37, 400 407.
25. LOBUGLIO AF, WHEELER RH, TRANG J, HAYNES A, ROGERS K, HARVEY EB, SUN L, GRAYEB J AND KHAZAELI MB. (1989). Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl Acad. USA, 86, 4220 4224.
26. LUITEN RM, FLEUREN GJ, WARNAAR SO AND LITVINOV SV. (1996). Target-specific activation of mast cells by immunoglobulin E reactive with a renal-cell-earcinoma-associated antigen. Lab. Invest., 74, 467 475.
27. MARUMO K, BABA S, MURAKI J, JITSUKAWA S, UENO M, HATA M, TACHIBANA M, TAZAKI H AND DEGUCHI N. (1989). Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinoma. Urology, 33, 219 225.
28. MEREDITH RF, LOBUGLIO AF, PLOTT WE, ORR RA, BREZOVICH IA, RUSSELL CD, HARVEY EB, YESTER MV, WAGNER AJ, SPENCER SA, WHEELER RH, SALEH MN, ROGERS KJ, POLANSKY A, SALTER MM AND KHAZAELI MB. (1991). Pharmacokinelics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J. Nucl. Med., 32, 1162 1168.
29. MEZZANZANICA D, CANEVARI S, MENARD S, PUPA SM, TAGLIABUE E, LANZAVECCHIA A AND COLNAGHI MI. (1988). Human ovarian carcinoma lysis by cytotoxic T cells targeted bybi-specific monoclonal antibodies: analysis of the antibody components. Int. J. Cancer, 41, 609 615.
30. MUSS HB, COSTANZI JJ, LEAVITT R, WILLIAMS RD, KEMPF RA, POLLARD R, OZER H, ZEKAN PJ, GRUNBERG SM, MITCHEL MS, CAPONERA M, GAVIGAN M, ERNEST ML, VENTURI C, GREINER JW AND SPIEGEL RJ. (1987). Recombinant alpha interferon: a randomizcd trial ol two routes of administration. J. Clin. Oncol., 5, 286 291.
31. NISTICO P, MORTARINI R, DEMONTE LB, MAZZOCCHI A, MARIANI M, MALAVASI F, PARMIANI G, NATALI PG AND ANICHINI A. (1992). Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to lysis in human melanoma. J. Clin. Invest., 90, 1093-1099.
32. OOSTERWIJK E, RUITER DJ, HOEDEMAEKER PJ, PAUWELS EKJ, JONAS U, ZWARTENDIJK J AND WARNAAR SO. (1986). Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer, 38, 489-494.
33. OOSTERWIJK E, BANDER NH, DIVGI CR, WELT S, WAKKA JC, FINN RD, CARSWELL EA, LARSON SM, WARNAAR SO, FLEUREN GJ, OETTGEN HF AND OLD LJ. (1993). Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol., 11, 738 750.
34. PALMER PA, VINKE J, EVERS P, POURREAU C, OSKAM R, ROEST G, VLEMS F, BECKER L, LORIAUX E AND FRANKS CR. (1992). Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur. J. Cancer, 28A, 1038-1044.
35. PARKINSON DR, FISHER RI, RAYNER AA, PAIETTA E, MARGOLIN KA, WEISS GR, MIER JW, SZNOE M, GAYNOR ER, BAR MH, GUCALP R, BOLDT DH, MILLS B AND HAWKINS MJ. (1990). Therapy of renal cell carcinoma with interleukin-2 and lympholine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J. Clin. Oncol., 8, 1630-1636.
36. QIAN JH, TITUS JA, ANDREW SM, MEZZANZANICA D, GARRIDO MA, WUNDERLICH JR AND SEGAL DM. (1991). Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J. Immunol., 146, 3250-3256.
37. RAVENSWAAY CLAASEN VAN HH, GRIENDT VJ, MEZZANZANICA D, BOLHUIS RLH, WARNAAR SO AND FLEUREN GJ. (1993). Analysis of production, purification, and cytolytic potential of bispecific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int. J. Cancer, 55, 128-136.
38. RIVA P, TISON V, ARISTA A, STURIALE C, FRANCESCHI G, RIVA N, CASI M, MOSCATELLI G, CAMPORI F AND SPINELLI A. (1993). Radioimmunotherapy of gastrointestinal cancer and glioblastomas. Int. J. Biol. Markers, 8, 192 197.
39. ROSENBERG SA, LOTZE MT, YANG JC, AEBERSOLD PM, LINEHAN WM, SEIPP CA AND WHITE DE. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210, 474-484.
40. SALEH MN, KHAZAELI MB, GRIZZLE WE, WHEELER RH, LAWSON S, LIU T, RUSSELL C, MEREDITH R, SCHLOM J AND LOBUGLIO AF. (1993). A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res., 53, 4555-4562.
41. SCHROFF RW, FOO KH, BEATTY SM, OLDHAM RK AND MORGAN AC. (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., 45, 879.
42. SHAWLER DL, BARTHOLOMEW RM, SMITH LM AND DILLMAN RO. (1985). Human immune response to multiple injections of murine monoclonal IgG. J. Immunol., 135, 1530.
43. 2. J. Natl Cancer. Inst., 85, 1003-1004.
44. 2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer. Hybridoma, 13, 519-525.
45. WHITEHEAD RP, WARD D, HEMINGWAY L, HEMSTREET GP, III, BRADLEY E AND KONRAD M. (1990). Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res., 50, 6708 6715.